| 0.094 -0.012 (-11.32%) | 06-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.08 | 1-year : | 0.12 |
| Resists | First : | 0.06 | Second : | 0.1 |
| Pivot price | 0.04  |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0.03 |
MA(20) : | 0.04 |
| MA(100) : | 0.33 |
MA(250) : | 0.99 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 25.2 |
| RSI | RSI(14): 28.7 |
|||
| 52-week | High : | 2.46 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DMTK ] has closed above bottom band by 5.8%. Bollinger Bands are 59.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 27 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.02 - 0.02 | 0.02 - 0.02 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Mon, 24 Jun 2024
Why Is DermTech (DMTK) Stock Down 26% Today? - InvestorPlace
Tue, 18 Jun 2024
DermTech Restructures Amid Bankruptcy and Executive Retention - TipRanks
Tue, 18 Jun 2024
DermTech Files for Voluntary Chapter 11 Protection - Business Wire
Tue, 21 May 2024
DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44% - Simply Wall St
Sat, 02 Mar 2024
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate - Simply Wall St
Thu, 29 Feb 2024
DermTech Reports Fourth-Quarter 2023 Financial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 35 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 18 (%) |
| Shares Short | 3,020 (K) |
| Shares Short P.Month | 2,850 (K) |
| EPS | -2.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.13 |
| Profit Margin | 0 % |
| Operating Margin | -533.4 % |
| Return on Assets (ttm) | -38.6 % |
| Return on Equity (ttm) | -121.8 % |
| Qtrly Rev. Growth | 10.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.44 |
| EBITDA (p.s.) | -2.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -72 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.01 |
| Price to Sales | 0.03 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|